1. Home
  2. NKX vs ARVN Comparison

NKX vs ARVN Comparison

Compare NKX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

N/A

Current Price

$10.58

Market Cap

640.3M

Sector

Finance

ML Signal

N/A

Logo Arvinas Inc.

ARVN

Arvinas Inc.

N/A

Current Price

$7.52

Market Cap

600.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NKX
ARVN
Founded
2002
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
600.2M
IPO Year
2002
2018

Fundamental Metrics

Financial Performance
Metric
NKX
ARVN
Price
$10.58
$7.52
Analyst Decision
Buy
Analyst Count
0
16
Target Price
N/A
★ $13.93
AVG Volume (30 Days)
233.0K
★ 703.7K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
★ 4.37%
N/A
EPS Growth
N/A
★ 58.84
EPS
N/A
★ 1.70
Revenue
N/A
★ $262,600,000.00
Revenue This Year
N/A
$12.76
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$4.40
Revenue Growth
★ N/A
N/A
52 Week Low
$10.44
$6.97
52 Week High
$13.20
$14.22

Technical Indicators

Market Signals
Indicator
NKX
ARVN
Relative Strength Index (RSI) 14.82 38.45
Support Level N/A N/A
Resistance Level $13.16 $8.52
Average True Range (ATR) 0.16 0.31
MACD -0.07 -0.07
Stochastic Oscillator 6.69 32.09

Price Performance

Historical Comparison
NKX
ARVN

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: